-
No medicine and no injections, 2.5 hours a week, the risk of death is reduced by 70%!
Time of Update: 2022-08-19
According to the assessment and standards of preoperative and postoperative rehabilitation exercise in the "Chinese Breast Cancer Follow-up and Health Management Guidelines", after diagnosis of breast cancer, patients should avoid a sedentary lifestyle and resume their daily physical activities before the disease as soon as possible .
-
The survival data of the IMpower010 study was published for the first time, consolidating atezolizumab as the standard adjuvant therapy!
Time of Update: 2022-08-19
Previous data from IMpower010 (NCT02486718) demonstrated a statistically significant benefit in disease-free survival (DFS) with atezolizumab compared with best supportive care (BSC) in patients with NSCLC resected after platinum-based chemotherapy: PD-L1 tumor cells (TC) ≥ 1% II-IIIA patients (DFS HR=0.
-
Voice of China: The first domestic PD-1 inhibitor combined with double platinum chemotherapy for neoadjuvant treatment of stage IIB-IIIB NSCLC is safe and effective!
Time of Update: 2022-08-19
This study is a single-center prospective study to investigate the efficacy and safety of neoadjuvant toripalizumab (the first PD-1 inhibitor in China) plus double platinum chemotherapy in the treatment of stage IIb-IIIb non-small cell lung cancer .
-
Cell Metabolism: Lin Jianshui's team found that fat cells can produce a hormone that inhibits liver cancer
Time of Update: 2022-08-19
Jianpi Lin from the University of Michigan Medical Center published a research paper entitled: Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment in Cell Metabolism, a sub-journal of Cell .
-
Radiology: The value of artificial intelligence assessment in breast cancer mammography screening
Time of Update: 2022-08-19
Recently, a study published in the journal Radiology compared the diagnostic performance of commercially available artificial intelligence systems with independent double-reading performed by radiologists at BreastScreen in Norway, while also exploring the histopathological features of breast cancer with different AI scores.
-
J Clin Oncol: Ripatinib vs sunitinib in the late-line treatment of advanced gastrointestinal stromal tumors
Time of Update: 2022-08-19
In conclusion, ripatinib did not demonstrate superior properties to sunitinib in terms of progression-free survival in patients with advanced gastrointestinal stromal tumors .
In conclusion, ripatinib did not demonstrate superior properties to sunitinib in terms of progression-free survival in patients with advanced gastrointestinal stromal tumors .
-
European Radiology: Application of deep learning-based ultrasound nomogram model in preoperative prediction of pancreatic neuroendocrine tumor aggressiveness
Time of Update: 2022-08-19
Recently, published in European Radiology, combining CEUS image-based DL with clinical factors to develop and validate a combined nomogram model for personalized prediction of preoperative tumor aggressiveness in patients with PNENs for accurate preoperative risk profiling.
-
Cancer is no longer "certain death", and cure is not delusional!
Time of Update: 2022-08-19
Video applet like, double-tap to cancel the like and watch, double-tap to cancel the view Cancer cure is no longer a "delusion"With the development of medical technology, cancer is no longer a "mortal" terminal disease, and the cure rate of cancer is increasing year by year .
-
Why are men at higher risk of cancer?
Time of Update: 2022-08-19
A recent risk-assessment study of nearly 300,000 people suggests that biological differences inherent in men and women are a potential cause of differences in cancer rates .
-
J Clin Oncol: Long-term outcomes of rituximab combined with lenalidomide or chemotherapy in follicular lymphoma
Time of Update: 2022-08-19
The RELEVANCE trial is a Phase 3 clinical trial to compare lenalidomide + rituximab (R2) vs rituximab + chemotherapy (R-chemo) in patients with previously untreated advanced FL efficacy and safety .
-
European Radiolog: Deep Learning Improves Radiologists' Performance in CT Bone Metastasis Detection
Time of Update: 2022-08-19
Deep learning-based algorithm improved radiologists' performance in bone metastases detection on CT.
Deep learning-based algorithm improved radiologists' performance in bone metastases detection on CT.
Deep learning-based algorithm improved radiologists' performance in bone metastases detection on CT.
-
Express treatment of HER2-positive breast cancer, blockbuster ADC has made positive progress
Time of Update: 2022-08-19
▎Edited by WuXi AppTec Content TeamReferences: [1] ENHERTU® Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer.
-
British Journal of Cancer: Eat while it's hot, it will cause cancer
Time of Update: 2022-08-19
Recently, the team of Li Zhiyuan from Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences published a research paper entitled: Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma in the British Journal of Cancer.
-
Adjuvant therapy for non-HER2-positive breast cancer patients
Time of Update: 2022-08-19
In the recommendation of hormone receptor-positive HER2-negative postoperative adjuvant chemotherapy, genetic testing tools are used to stratify intermediate-risk patients .
In the recommendation of hormone receptor-positive HER2-negative postoperative adjuvant chemotherapy, genetic testing tools are used to stratify intermediate-risk patients .
-
European Radiology: Measurement of this imaging marker predicts chemotherapy-associated steatohepatitis in breast cancer patients receiving NAC!
Time of Update: 2022-08-19
A study published in European Radiology recently quantified liver fat content by MRI mDIXON-Quant examination to determine the prevalence of CASH, and semi-automated volume analysis software to measure EAT volume on chest CT to explore BC patients after NAC.
-
Zhou Caicun's team won the 2022 WCLC Cancer Treatment Team Award, the only one in Asia!
Time of Update: 2022-08-19
The team of Professor Zhou Caicun, Department of Oncology, Shanghai Pulmonary Hospital, won the Cancer Treatment Team Award (CCTA) issued by the International Association for the Study of Lung Cancer (IASLC), becoming the four recipients of the award in the world this year.
-
European Radiology: Radiomics enables non-invasive prediction of EGFR mutation status in GGO lung adenocarcinoma!
Time of Update: 2022-08-19
The established radiomics model containing 102 features showed strong discriminative power for EGFR mutation status (mutant or wild-type), with better predictive power than clinical models (AUC: 0.
-
Ultra-high survival rate and disease control rate, proton heavy ion precision radiotherapy can effectively improve the prognosis of patients with osteosarcoma!
Time of Update: 2022-08-19
▲ Source: reference source [1]Proton heavy ion treatment of osteosarcoma has a control rate of 92%In 2017, a clinical study conducted by Japanese researchers and published in "Int J Radiat Oncol Biol Phys" analyzed the effect of proton-heavy ion therapy on bone and soft tissue tumors.
-
For this part of early breast cancer patients, adjuvant chemotherapy is useless!
Time of Update: 2022-08-19
Multivariate Cox analysis was performed to investigate the effect of adjuvant chemotherapy on T1a, T1b and T1cN0M0 BC, including various tumor grades and four molecular subtypes .
-
J Ethnopharmacol: Combining network pharmacology and transcriptomic validation to study the efficacy and mechanism of Mufangji decoction in the prevention of lung cancer
Time of Update: 2022-08-19
The targets and pathways of MFJD in the treatment of lung cancer were obtained through protein-protein interactions, molecular docking, and the David database, and the predicted results were validated in vitro and in vivo .
